Life Settlement Assets PLC Reports Strong Final Results for 2025 with Improved Cash Position and Special Dividends

Policy maturities of USD 20.6 million show the Life Settlement Assets engine is still working

Maturities are the lifeblood of this sort of trust. In 2025, LSA declared maturities totalling USD 20.6 million, split between USD 11.9 million from non-HIV policies and USD 8.7 million from HIV policies.

That is important because it shows the portfolio is converting into real outcomes rather than just paper valuations. The chairman also said the company had positive actual-to-expected ratios across both policy segments, which suggests maturities were coming through at least as well as forecast.

LSA also said it ended the year in a strong cash position, although the exact cash figure was not disclosed in this RNS. For investors, that missing number is slightly frustrating, but the follow-on dividend and buyback activity does lend some weight to the board’s confidence.

MBC Action proceeds could add another 2026 catalyst for Life Settlement Assets

There is another moving part here: the Mutual Benefits Keep Policy Trust, or MBC, action. Administrative arrangements are nearing finalisation and the final proceeds are expected to be received during 2026.

This matters because extra proceeds could further support cash returns or strengthen the company’s balance sheet. The exact amount expected was not disclosed, so investors should treat this as a potential positive rather than money already in the bag.

Special dividends and share buybacks are a clear shareholder return story

LSA did not just talk about returns – it actually paid them. During 2025, the company declared a special dividend of 4.5307 cents per share, totalling USD 2.0 million, paid on 30 October 2025.

After the year end, it went again with a bigger special dividend of 6.7960 US cents per share, totalling USD 3.0 million, paid on 14 April 2026. Two special dividends in fairly quick succession tells you the board is comfortable enough with the cash position to release capital.

Buybacks also continued. In 2025 the company bought back and cancelled 1,259,474 shares, representing 2.8% of the issued share capital as at 31 December 2024, at a total cost of USD 2.2 million.

Since the year end it has bought back and cancelled a further 415,954 shares at a total cost of USD 0.7 million, equal to 0.9% of the issued share capital as at 31 December 2025. As at the report date, there were 43,727,515 shares in issue.

That combination of dividends and buybacks is hard to dislike. It gives shareholders direct cash today and can improve value per remaining share if buybacks are done at an attractive discount to underlying NAV, although the discount level was not disclosed in this announcement.

Costs are under control in cash terms, but the ongoing charges ratio has gone the wrong way

Now for the less flattering bit. LSA said total costs were marginally lower in 2025 despite inflationary pressures, which is a good operational sign.

However, the ongoing charges ratio rose from 5.0% to 5.4% of average net assets. Excluding policy servicing fees and legal costs, it also increased from 2.7% to 3.0%.

The company says that rise was due to the effect of share buybacks and dividends. That explanation makes sense mechanically because when net assets reduce, fixed costs can eat up a bigger percentage, but it is still not ideal. A 5.4% ongoing charges ratio is a number investors should watch closely, especially in a specialist trust where returns can already be lumpy.

Chairman outlook for 2026 points to more cash returns if conditions hold

Michael Baines struck a confident tone. He highlighted the three core priorities as accurate NAV forecasting, cost control and delivering returns to shareholders.

The standout comment was that the board will continue to explore opportunities to provide satisfactory returns through dividends and share repurchases. That is exactly what income-focused and discount-focused investors will want to hear.

The more optimistic stance on future cash inflows is also notable because it suggests management believes the portfolio transition is becoming easier to read. If that proves right, 2026 could be another year where realised cash, rather than just valuation discussion, drives the story.

What this Life Settlement Assets final results announcement means for retail investors

My view is that this is a positive update overall. The mix of an improved view on the HIV portfolio, USD 20.6 million of maturities, a strong cash position, and two special dividends makes this look like a business that is currently doing what shareholders need it to do.

The caution flags are not hard to spot either. Part of the good news comes from a model update rather than hard cash, the ongoing charges ratio is high and moving higher, and the size of the cash pile and the expected MBC proceeds were not disclosed here.

Even so, this RNS reads better than many specialist asset trust updates because it contains tangible shareholder returns, not just hopeful language. If LSA can keep maturities coming through, maintain cash discipline and avoid costs drifting further, the investment case looks firmer than it did a year ago.

In short, this was a good set of final results from Life Settlement Assets PLC. Not perfect, but definitely heading in the right direction.